These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1431345)

  • 1. Diagnostic applications and therapeutic approaches with different preparations of anti-CEA antibodies.
    Bischof Delaloye A; Delaloye B
    Int J Biol Markers; 1992; 7(3):193-7. PubMed ID: 1431345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
    Peña Y; Perera A; Batista JF
    MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies].
    Oriuchi N
    Gan To Kagaku Ryoho; 1999 May; 26(6):762-7. PubMed ID: 10410144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoscintigraphy with 99mTc-labelled anti-CEA monoclonal antibody in colorectal carcinoma.
    Vieira MR; Rodrigues M; Salgado L; Santos R; de Almeida JC; Manoel LO; de Almeida JM
    Eur J Surg Oncol; 1993 Jun; 19(3):294-9. PubMed ID: 8314389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
    Goldenberg DM; Juweid M; Dunn RM; Sharkey RM
    J Nucl Med Technol; 1997 Mar; 25(1):18-23; quiz 34. PubMed ID: 9239599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
    J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.
    Larson SM
    Cancer Invest; 1993; 11(2):235-8. PubMed ID: 8462025
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.
    Hertel A; Baum RP; Lorenz M; Baew-Christow T; Encke A; Hör G
    Br J Cancer Suppl; 1990 Jul; 10():34-6. PubMed ID: 2166552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer imaging with CEA antibodies: historical and current perspectives.
    Goldenberg DM
    Int J Biol Markers; 1992; 7(3):183-8. PubMed ID: 1431343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeting strategies for radio-immunoguided tumour localisation and therapy.
    Stoldt HS; Aftab F; Chinol M; Paganelli G; Luca F; Testori A; Geraghty JG
    Eur J Cancer; 1997 Feb; 33(2):186-92. PubMed ID: 9135486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEA-immunoscintigraphy with 99m-technetium correlates with tumour cell differentiation in colorectal cancer.
    Wittig BM; Hach A; Hahn K; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1993; 29A(9):1327-9. PubMed ID: 8343279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
    J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of tumor receptors for diagnostic imaging. A review.
    Hirai H
    Acta Radiol Suppl; 1990; 374():57-64. PubMed ID: 1726378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of solid tumors: from fairytale to reality.
    Adams GP; Weiner LM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):9-11. PubMed ID: 11279802
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.
    Moffat FL; Pinsky CM; Hammershaimb L; Petrelli NJ; Patt YZ; Whaley FS; Goldenberg DM
    J Clin Oncol; 1996 Aug; 14(8):2295-305. PubMed ID: 8708720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.